CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
-2.2%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.47B
AUM Growth
+$1.47B
(-2%)
Cap. Flow
-$122M
Cap. Flow
% of AUM
-8.29%
Top 10 Holdings %
Top 10 Hldgs %
63.82%
Holding
43
New
4
Increased
15
Reduced
6
Closed
8
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$51.2M |
| 2 |
Vaxcyte
PCVX
|
$33.6M |
| 3 |
Alkermes
ALKS
|
$33.1M |
| 4 |
Cogent Biosciences
COGT
|
$27.9M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$22.9M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$163M |
| 2 |
Merus
MRUS
|
$68.6M |
| 3 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$54.5M |
| 4 |
Vera Therapeutics
VERA
|
$25M |
| 5 |
Kyverna Therapeutics
KYTX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 99.48% |
| 2 | Financials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $189M | 12.92% | 3,200,000 -1,160,000 | -27% | -$68.6M |
|
2
Nuvalent
NUVL
$5.52B
| $113M | 7.7% | 1,487,756 | – | – |
|
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $107M | 7.33% | 2,754,266 +586,473 | +27% | +$22.9M |
|
|
4
Vaxcyte
PCVX
$4B
| $98.5M | 6.73% | 1,305,000 +445,000 | +52% | +$33.6M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $92.9M | 6.34% | 3,973,245 | – | – |
|
|
6
Vera Therapeutics
VERA
$1.38B
| $89.5M | 6.11% | 2,475,000 -690,000 | -22% | -$25M |
|
|
7
Cogent Biosciences
COGT
$1.69B
| $82.1M | 5.6% | 9,738,000 +3,313,000 | +52% | +$27.9M |
|
|
8
Soleno Therapeutics
SLNO
$3.6B
| $58.1M | 3.97% | 1,425,000 +1,255,467 | +741% | +$51.2M |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $52.7M | 3.6% | 1,425,000 +558,532 | +64% | +$20.7M |
|
10
MindMed
MNMD
$676M
| $51.5M | 3.52% | 7,145,888 +1,312,555 | +23% | +$9.46M |
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $50.3M | 3.43% | 1,225,000 +175,000 | +17% | +$7.19M |
|
12
Arvinas
ARVN
$568M
| $50.2M | 3.42% | 1,884,361 +609,361 | +48% | +$16.2M |
|
13
Spyre Therapeutics
SYRE
$996M
| $46.7M | 3.19% | 1,988,084 +104,000 | +6% | +$2.45M |
|
|
14
Perspective Therapeutics
CATX
$250M
| $46.4M | 3.17% | 4,657,345 -16,395,286 | -78% | -$163M |
|
15
Pharvaris
PHVS
$1.39B
| $34M | 2.32% | 1,810,175 +85,175 | +5% | +$1.6M |
|
|
16
Alkermes
ALKS
$4.78B
| $33.1M | 2.26% | +1,375,000 | New | +$33.1M |
|
17
Viridian Therapeutics
VRDN
$1.5B
| $32.9M | 2.25% | 2,528,032 +593,379 | +31% | +$7.72M |
|
18
Kura Oncology
KURA
$686M
| $32.8M | 2.24% | 1,593,350 +68,350 | +4% | +$1.41M |
|
19
Nkarta
NKTX
$151M
| $24.5M | 1.67% | 4,151,034 +986,034 | +31% | +$5.83M |
|
20
Celcuity
CELC
$2.17B
| $24M | 1.64% | 1,464,105 -91,849 | -6% | -$1.5M |
|
|
THRD
21
DELISTED
Third Harmonic Bio
THRD
| $20.1M | 1.37% | 1,545,426 +295,426 | +24% | +$3.84M |
|
22
Immunovant
IMVT
$2.56B
| $19.8M | 1.35% | 750,990 | – | – |
|
|
ABVX
23
Abivax
ABVX
$6.12B
| $17M | 1.16% | 1,284,110 -610,893 | -32% | -$8.08M |
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.9M | 1.16% | 825,000 +506,149 | +159% | +$10.4M |
|
25
C4 Therapeutics
CCCC
$185M
| $15.8M | 1.08% | 3,410,384 | – | – |
|